| 56.4 -0.69 (-1.21%) | 04-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 70.06 | 1-year : | 81.83 |
| Resists | First : | 59.99 | Second : | 70.06 |
| Pivot price | 57.94  |
|||
| Supports | First : | 55.38 | Second : | 52.54 |
| MAs | MA(5) : | 58.1 |
MA(20) : | 57.18 |
| MA(100) : | 47.24 |
MA(250) : | 40.41 |
|
| MACD | MACD : | 1.6 |
Signal : | 2.1 |
| %K %D | K(14,3) : | 54.9 |
D(3) : | 71.5 |
| RSI | RSI(14): 51.7 |
|||
| 52-week | High : | 63.95 | Low : | 28.19 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ XENE ] has closed above bottom band by 10.9%. Bollinger Bands are 48.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 57.04 - 57.37 | 57.37 - 57.72 |
| Low: | 54.85 - 55.21 | 55.21 - 55.6 |
| Close: | 55.72 - 56.35 | 56.35 - 57.03 |
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Mon, 20 Apr 2026
Xenon Pharmaceuticals (XENE) Reports Positive Phase 3 Study Resu - GuruFocus
Sun, 19 Apr 2026
Xenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results for Azetukalner in Focal Onset Seizures at AAN 2026 - Quiver Quantitative
Sat, 18 Apr 2026
RBC Raises Xenon Price Target, Cites Phase III Optimism for Epilepsy Drug - MSN
Thu, 16 Apr 2026
Xenon to Present at Upcoming Investor Conferences - Sahm
Wed, 15 Apr 2026
Xenon lines up four investor conference presentations in Q2 2026 - Stock Titan
Mon, 13 Apr 2026
Xenon Pharmaceuticals (XENE) boosts 2025 inducement equity plan share reserve - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 95 (M) |
| Held by Insiders | 7.836e+007 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 5,530 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.7053e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 974.2 % |
| Return on Equity (ttm) | -32.6 % |
| Qtrly Rev. Growth | 7.5e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -69.02 |
| EBITDA (p.s.) | -3.91253e+008 |
| Qtrly Earnings Growth | -4.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -279 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.82 |
| Price to Cash Flow | 5.81 |
| Dividend | 0 |
| Forward Dividend | 4.85e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|